Navigation Links
'If Hamlet give the first or second hit': The development of Burkitt's lymphoma
Date:11/8/2011

The human c-myc gene encodes a transcription factor (MYC) involved in the regulation of a vast number of other genes it has been estimated that the transcription of about one in six genes is somehow under the control of MYC. Perhaps because of MYC's wide range of targets, mutations of the c-myc gene are frequently associated with a variety of tumours, not only with Burkitt's lymphoma. Mutations that lead to excessive amounts of the MYC protein are particularly threatening.

It has long been known that Burkitt's lymphoma only develops when MYC is mutated or overexpressed, although experiments in mice have shown that some animals live quite happily and healthily with higher levels of the MYC protein. This observation is consistent with the "second hit" model for the origin of cancer: as well as a change to c-myc, a second gene must also be disturbed before disease is initiated. In the case of lymphomas, the second hit is often in the p53 or the Bcl2 gene. Loss of p53 or increased amounts of the BCL2 protein are both associated with lymphoma. But how does the course of the disease relate to the nature of the second hit?

This question has now been investigated by Sexl's and Stoiber's groups. Using a mouse model of human lymphoma, the scientists compared the effects on the immune system of deleting the p53 gene or over-activating the Bcl2 gene, or both. The results were dramatic. If the p53 gene was mutated, the resulting tumours were no longer recognized and killed by the mouse's immune system. In other words, such tumours escaped the mouse's normal "surveillance" mechanism and went on to cause full-blown lymphoma. On the other hand, if instead the Bcl2 gene was overexpressed (to produce more BCL2 protein), the mouse's immune system could recognize and attack the tumour cells, thereby slowing or preventing cancer development. If both the p53 and the Bcl2 genes were affected, immune recognition remained efficient, in other words the Bcl2 effect is dominant.

The results show for the first time that the nature of the "second hit" determines whether the animals are able to mount an immune response against the developing lymphoma. Interestingly, Sexl's collaboration partner Ulrich Jger from the Medical University of Vienna has obtained preliminary data from human patients that are consistent with the results in mice. The collaboration shows once again the value of comparative medicine in understanding the progression of human diseases.

The findings have extremely important consequences for tumour therapy in humans. First, because of the association of high BCL2 levels with tumour development, a number of pharmaceutical companies are currently developing BCL2 inhibitors for use in cancer therapy. As Sexl points out, though, "The inhibitors may have the unwanted effect of preventing the natural immune reaction. It will be important to evaluate the consequences of BCL2 inhibition carefully taking the host immune system fully into account to ensure that the drugs have no harmful side-effects." Secondly, the results may potentially shape future immunotherapeutic approaches, as whether a tumour overexpresses Bcl2 or does not express p53 clearly has a dramatic influence on the course of disease.


'/>"/>
Contact: Prof Veronika Sexl
veronika.sexl@vetmeduni.ac.at
43-125-077-2910
University of Veterinary Medicine -- Vienna
Source:Eurekalert

Related medicine news :

1. UGA researchers develop first mouse model to study important aspect of Alzheimer’s
2. New study from NYUCN is the first to look at nursing error disclosure in nursing homes
3. Cardiovascular magnetic resonance now an important first-line test
4. UK HealthCare surgeons are first to perform novel procedures prior to transplant
5. First-of-its-kind study creates new tool for targeted cancer drug development
6. Clinical trial shows first evidence that anal cancer is preventable
7. Henry Ford Hospital first in United States to offer MKTP surgery as treatment option for vitiligo
8. Veterinary researchers discover first US strains of hepatitis E virus from rabbits
9. First report of increased safety using simultaneous techniques for cardiac testing published
10. UGA scientists team up to define first-ever sequence of biologically important carbohydrate
11. New national research center for bowel disease in London will be a UK first
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... 2017 , ... The next Patient Care Academy at Kalamazoo Valley Community College ... complete the seven-week long Patient Care Academy are eligible to take the State of ... a CNA in Kalamazoo is $24,428.* , As a CNA, one is equipped for ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... Ten outstanding ... Union's Stars in the Classroom and will win a visit by a Houston Texans ... K-12 who are at least five years old can visit texanschecking.com/stars to nominate their ...
(Date:8/16/2017)... ... August 16, 2017 , ... In 1987, ... celebrate 30 years in business this year, and they’re marking the milestone by ... to serve their patients. , It stands to reason that, given the ...
(Date:8/16/2017)... ... August 16, 2017 , ... Maury Regional Health has announced ... draws. By broadly deploying AccuVein devices, Maury Regional Medical Center is making vein visualization ... out of a needle stick and more importantly, helps our staff members locate a ...
(Date:8/16/2017)... ... 16, 2017 , ... A global leader in the treatment of clubfoot, ... 29 Indian states—bringing the country one step closer to eliminating clubfoot as a lifelong ... is on track to enroll 10,000 children in the clubfoot treatment program in this ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... 2017 Insightin Health, provider of data-driven ... engagement, announced the selection of Michael Wood ... effective as of February 2017. In this role, Wood ... for our clients. Wood brings with him more ... business analytics within the healthcare industry. Wood formerly ...
(Date:8/7/2017)... (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced financial ... unless otherwise noted, are to the quarter ended June 30, ... 2017 Highlights include: Revenue of $1,126 ... Total prescriptions dispensed of 220,000, compared to 241,000 ... Gross profit per prescription dispensed of $371, ...
(Date:8/4/2017)... 3, 2017  Agragen, LLC, a ... the biopharmaceutical, nutraceutical, and aquacultural feed sectors, announces ... lead drug candidates, AGR131.  This drug is designed ... the blood of patients suffering from inflammatory conditions ... disease. Biological ...
Breaking Medicine Technology: